This study is testing a new medicine called tulisokibart for Crohn's disease, a condition where the digestive system is inflamed. It aims to find out if tulisokibart helps more than a placebo (a pill with no medicine) in reducing symptoms and signs of Crohn's disease. There are two parts to the study: Study 1 (lasting 52 weeks) includes both starting and continuing treatment, and Study 2 (lasting 12 weeks) only includes starting treatment. Participants must have had Crohn's disease for at least 3 months and have tried other treatments without success. People with certain other health conditions, like ulcerative colitis or active infections, cannot join.
- Length: Study 1 lasts 52 weeks, Study 2 lasts 12 weeks.
- Visits: Regular check-ups are required to monitor progress.
- Risks: Includes possible side effects of tulisokibart.
How understandable was the trial content above?
Hard to understand
Easy to understand